<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:40:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:11053360" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:11053360</identifier>
        <datestamp>2024-04-27</datestamp>
        <setSpec>ijneuro</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Int J Neuropsychopharmacol</journal-id>
              <journal-id journal-id-type="publisher-id">ijnp</journal-id>
              <journal-title-group>
                <journal-title>International Journal of Neuropsychopharmacology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1461-1457</issn>
              <issn pub-type="epub">1469-5111</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC11053360</article-id>
              <article-id pub-id-type="pmcid">PMC11053360</article-id>
              <article-id pub-id-type="pmc-uid">11053360</article-id>
              <article-id pub-id-type="pmid">38573154</article-id>
              <article-id pub-id-type="pmid">38573154</article-id>
              <article-id pub-id-type="doi">10.1093/ijnp/pyae017</article-id>
              <article-id pub-id-type="publisher-id">pyae017</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Regular Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00415</subject>
                  <subject>AcademicSubjects/SCI01870</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sajid</surname>
                    <given-names>Sumra</given-names>
                  </name>
                  <aff><institution>New York State Psychiatric Institute</institution>, <addr-line>New York, New York</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Galfalvy</surname>
                    <given-names>Hanga C</given-names>
                  </name>
                  <aff><institution>Columbia University Irving Medical Center and New York State Psychiatric Institute</institution>, <addr-line>New York, New York</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keilp</surname>
                    <given-names>John G</given-names>
                  </name>
                  <aff><institution>Columbia University Irving Medical Center and New York State Psychiatric Institute</institution>, <addr-line>New York, New York</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Burke</surname>
                    <given-names>Ainsley K</given-names>
                  </name>
                  <aff><institution>Columbia University Irving Medical Center and New York State Psychiatric Institute</institution>, <addr-line>New York, New York</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mann</surname>
                    <given-names>J John</given-names>
                  </name>
                  <aff><institution>Columbia University Irving Medical Center and New York State Psychiatric Institute</institution>, <addr-line>New York, New York</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Grunebaum</surname>
                    <given-names>Michael F</given-names>
                  </name>
                  <aff><institution>Columbia University Irving Medical Center and New York State Psychiatric Institute</institution>, <addr-line>New York, New York</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="c1" ref-type="corresp"/>
                  <!--michael.grunebaum@nyspi.columbia.edu-->
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Correspondence: Michael F. Grunebaum, 1051 Riverside Drive, New York, NY 10032, USA (<email>michael.grunebaum@nyspi.columbia.edu</email>)</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2024</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2024-04-04">
                <day>04</day>
                <month>4</month>
                <year>2024</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>04</day>
                <month>4</month>
                <year>2024</year>
              </pub-date>
              <volume>27</volume>
              <issue>4</issue>
              <elocation-id>pyae017</elocation-id>
              <history>
                <date date-type="received">
                  <day>02</day>
                  <month>1</month>
                  <year>2024</year>
                </date>
                <date date-type="accepted">
                  <day>03</day>
                  <month>4</month>
                  <year>2024</year>
                </date>
                <date date-type="editorial-decision">
                  <day>26</day>
                  <month>3</month>
                  <year>2024</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>27</day>
                  <month>4</month>
                  <year>2024</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of CINP.</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="pyae017.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Objective</title>
                  <p>We sought to explore relationships of acute dissociative effects of intravenous ketamine with change in depression and suicidal ideation and with plasma metabolite levels in a randomized, midazolam-controlled trial.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>Data from a completed trial in suicidal, depressed participants (n = 40) randomly assigned to ketamine was used to examine relationships between ketamine treatment–emergent dissociative and psychotomimetic symptoms with pre/post-infusion changes in suicidal ideation and depression severity. Nonparametric correlational statistics were used. These methods were also used to explore associations between dissociative or psychotomimetic symptoms and blood levels of ketamine and metabolites in a subset of participants (n = 28) who provided blood samples immediately post-infusion.</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>Neither acute dissociative nor psychotomimetic effects of ketamine were associated with changes in suicidal ideation or depressive symptoms from pre- to post-infusion. Norketamine had a trend-level, moderate inverse correlation with dissociative symptoms on Day 1 post-injection (<italic toggle="yes">P</italic>  = .064; <italic toggle="yes">P</italic> =.013 removing 1 outlier). Dehydronorketamine correlated with Clinician-Administered Dissociative States Scale scores at 40 minutes (<italic toggle="yes">P</italic> = .034), 230 minutes (<italic toggle="yes">P</italic> = .014), and Day 1 (<italic toggle="yes">P</italic> = .012).</p>
                </sec>
                <sec id="s4">
                  <title>Conclusion</title>
                  <p>We did not find evidence that ketamine’s acute, transient dissociative, or psychotomimetic effects are associated with its antidepressant or anti-suicidal ideation actions. The correlation of higher plasma norketamine with lower dissociative symptoms on Day 1 post-treatment suggests dissociation may be more an effect of the parent drug.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Ketamine</kwd>
                <kwd>dissociation</kwd>
                <kwd>depression</kwd>
                <kwd>suicidal ideation</kwd>
                <kwd>plasma metabolite</kwd>
              </kwd-group>
              <counts>
                <page-count count="8"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text position="float">
              <caption>
                <title>Significance Statement</title>
              </caption>
              <p>This paper explores the relationship between IV ketamine’s dissociative and psychotomimetic effects and its therapeutic action on depression and suicidal ideation. Ketamine has both antidepressant and anti-suicidal ideation effects, including in cases where traditional antidepressants may not be effective. Research remains divided on whether ketamine’s dissociative and psychotomimetic effects are important for its therapeutic use in psychiatry. The findings of this study may have implications for future research and refining the psychiatric use of ketamine.</p>
            </boxed-text>
            <sec id="s5">
              <title>INTRODUCTION</title>
              <p>Ketamine is a dissociative anesthetic drug, approved in 1970, with more recently discovered antidepressant and anti-suicidal ideation properties (<xref rid="CIT0055" ref-type="bibr">Zarate et al., 2006</xref>; <xref rid="CIT0020" ref-type="bibr">Grunebaum et al., 2018</xref>; <xref rid="CIT0049" ref-type="bibr">Wilkinson et al., 2018</xref>). Dissociation is an acute, transient effect of ketamine characterized by symptoms such as memory loss, detachment from oneself, a perception of distortion, and a blurred sense of identity (<xref rid="CIT0044" ref-type="bibr">Şar, 2014</xref>). Dissociation is a symptom present in psychiatric illnesses, including post-traumatic stress disorder (PTSD), depersonalization-derealization disorder, and dissociative identity disorder (<xref rid="CIT0009" ref-type="bibr">Boyer et al., 2022</xref>). Dissociation can also be a nonpathological, normal occurrence that includes daydreaming, fantasizing, and absorption in daily experiences. Both forms of dissociation involve a narrowing of attention and exclusion of other material from awareness, leading to altered consciousness (<xref rid="CIT0011" ref-type="bibr">Butler, 2006</xref>).</p>
              <p>There are several established research measures of dissociative symptoms including the Clinician-Administered Dissociative States Scale (CADSS) (<xref rid="CIT0007" ref-type="bibr">Bernstein and Putnam, 1986</xref>; <xref rid="CIT0010" ref-type="bibr">Bremner et al., 1998</xref>; <xref rid="CIT0051" ref-type="bibr">Wright and Loftus, 1999</xref>; <xref rid="CIT0046" ref-type="bibr">Studerus et al., 2010</xref>). It is uncertain what role, if any, dissociation plays in ketamine’s therapeutic effects, and the results of psychiatric research on this have been mixed.</p>
              <p>It has been hypothesized that psychedelic drug treatment induces neuronal excitations as well as synaptic plasticity, which promotes a fast-acting anti-depressive response (<xref rid="CIT0030" ref-type="bibr">Ly et al., 2018</xref>). These findings support the positive relationship between drug-induced mystical experiences and treatment outcomes in psilocybin studies, suggesting that the psychedelic aspects of drugs may improve mental health and overall well-being in some individuals (<xref rid="CIT0019" ref-type="bibr">Griffiths et al., 2011</xref>). However, the conflicting literature on ketamine-induced dissociation raises the question of whether it plays a mediating or necessary role in the anti-depressant response. Indeed, other researchers argue against the potential benefits of ketamine’s dissociative effects (<xref rid="CIT0025" ref-type="bibr">Krystal et al., 1994</xref>; <xref rid="CIT0006" ref-type="bibr">Berman et al., 2000</xref>).</p>
              <p>Ketamine’s hypothesized mechanism of antidepressant action involves the blockade of NMDA receptors on inhibitory neurons, leading to a glutamate spike that potentially triggers increased synaptic formation and strengthening, which is thought to reverse depression-induced synaptic loss (<xref rid="CIT0001" ref-type="bibr">Abdallah et al., 2018</xref>; <xref rid="CIT0053" ref-type="bibr">Zanos and Gould, 2018</xref>; <xref rid="CIT0032" ref-type="bibr">Matveychuk et al., 2020</xref>; <xref rid="CIT0034" ref-type="bibr">Milak et al., 2020</xref>; <xref rid="CIT0043" ref-type="bibr">Rosenbaum et al., 2023</xref>). Scientific literature has both supported and contested the idea that ketamine’s transient dissociative effect is integral to its therapeutic action. Some research suggests that the dissociative properties of ketamine contribute to its anti-depressant effect (<xref rid="CIT0028" ref-type="bibr">Luckenbaugh et al., 2014</xref>; <xref rid="CIT0013" ref-type="bibr">Correia-Melo et al., 2017</xref>; <xref rid="CIT0038" ref-type="bibr">Niciu et al., 2018</xref>). In one study, data from treatment-resistant (TR) inpatients with major depressive disorder (MDD) and bipolar disorder (BP) who received a subanesthetic ketamine infusion found that dissociative symptoms were associated with a reduction in depression symptoms at 230 minutes and 7 days post-infusion (<xref rid="CIT0028" ref-type="bibr">Luckenbaugh et al., 2014</xref>). In another study on TR patients with MDD or BP who received a ketamine infusion, it was found that the depersonalization subscale of the CADSS was most closely related to ketamine’s antidepressant response (<xref rid="CIT0038" ref-type="bibr">Niciu et al., 2018</xref>). A retrospective chart review of those with TR or bipolar depression who received IV subanesthetic esketamine found that one-tenth of the participants experienced mild to extreme dissociative symptoms. Two-thirds of individuals experiencing dissociation remitted from depression within 3 weeks after esketamine infusion. However, the study did not compare remission rates between those with or without dissociative symptoms (<xref rid="CIT0013" ref-type="bibr">Correia-Melo et al., 2017</xref>). Other subjective effects during drug administration, such as “happiness” (<xref rid="CIT0012" ref-type="bibr">Chen et al., 2020</xref>) or “lightness,” are associated with antidepressant benefits (<xref rid="CIT0045" ref-type="bibr">Stocker et al., 2019</xref>).</p>
              <p>However, other research suggests that ketamine’s dissociative properties are more likely an undesirable side effect (<xref rid="CIT0047" ref-type="bibr">Valentine et al., 2011</xref>; <xref rid="CIT0036" ref-type="bibr">Murrough et al., 2013</xref>; <xref rid="CIT0002" ref-type="bibr">Acevedo-Diaz et al., 2020</xref>; <xref rid="CIT0034" ref-type="bibr">Milak et al., 2020</xref>; <xref rid="CIT0031" ref-type="bibr">Mathai et al., 2023</xref>). For example, one study found that floating, a depersonalization effect, was not related to ketamine’s anti-depressant response (<xref rid="CIT0002" ref-type="bibr">Acevedo-Diaz et al., 2020</xref>). Another study found that dissociative symptoms in a sample of participants with MDD were not correlated with changes in depressive symptoms (<xref rid="CIT0047" ref-type="bibr">Valentine et al., 2011</xref>). A separate post hoc analysis from clinical trials of intra-nasal esketamine for treatment-resistant depression found no association between dissociation and antidepressant effect (<xref rid="CIT0031" ref-type="bibr">Mathai et al., 2023</xref>).</p>
              <p>The lack of consensus in the literature has been attributed to reasons including functional unblinding and ketamine’s variable effect in patients with treatment-resistant depression compared with healthy individuals. Furthermore, the CADSS was developed for individuals with PTSD, and there are questions whether it is an adequate measure for acute, drug-induced dissociation (<xref rid="CIT0003" ref-type="bibr">Ballard and Zarate, 2020</xref>).</p>
              <p>With the goal of adding to this knowledge gap, we conducted an exploratory analysis to examine the relationships of acute and sub-acute post-infusion dissociative and psychotomimetic symptoms to clinical efficacy using data from the ketamine-randomized group (n = 40) in our completed, midazolam-controlled trial of IV ketamine in suicidal, depressed inpatients (<xref rid="CIT0020" ref-type="bibr">Grunebaum et al., 2018</xref>). In a subset that provided post-infusion blood samples (n = 28), we also explored relationships of dissociative and psychotomimetic effects to plasma levels of ketamine and metabolites.</p>
            </sec>
            <sec sec-type="materials" id="s6">
              <title>METHODS</title>
              <sec id="s7">
                <title>Participants</title>
                <p>A prior, completed randomized trial of IV ketamine vs midazolam enrolled depressed and suicidal adults (n = 80). The protocol was approved by the institutional review board of the New York State Psychiatric Institute (NYSPI). Participants were recruited via the internet, local advertisements, and clinician referrals. Study eligibility criteria included: 18–65 years old, DSM-IV diagnosis of MDD, score ≥4 on the Scale for Suicidal Ideation (SSI), and a score ≥16 on the 17-item Hamilton Depression Rating Scale (HDRS) (<xref rid="CIT0022" ref-type="bibr">Hamilton, 1960</xref>; <xref rid="CIT0004" ref-type="bibr">Beck et al., 1979</xref>). Exclusion criteria included: unstable medical or neurological condition, significant electrocardiographic abnormality, pregnancy or lactation, psychosis, history of ketamine or alcohol abuse within the past 6 months, suicidal ideation due to substance use or withdrawal, prior adverse reaction to ketamine or midazolam, a score &lt;25 on the Mini-Mental State Examination for persons older than 60 years, and lack of capacity to consent or inadequate understanding of English. All eligible and enrolled patients provided written informed consent as approved by the NYSPI institutional review board. Patients were admitted to an inpatient research unit at NYSPI. Participants were randomly assigned, double-blind, to either ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg) in a 100-mL saline infusion over 40 minutes. Patients’ blood pressure, O<sub>2</sub> saturation, heart rate, and respiratory rate were monitored every 5 minutes. Patients received post-infusion open clinical inpatient treatment and were discharged when assessed as stable and not an imminent safety risk. Participants received standard clinical treatment after hospital discharge, with weekly observational research ratings for the first 6 weeks. <xref rid="T1" ref-type="table">Table 1</xref> summarizes the frequency, median, SD, mean, and score ranges of study measures.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>Median (m) and range values (R) for each timepoint and outcome measure</p>
                  </caption>
                  <table frame="hsides" rules="groups" width="100%" border="1">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" colspan="2" rowspan="1">Schedule of research measures</th>
                        <th align="center" rowspan="1" colspan="1">Baseline</th>
                        <th align="center" rowspan="1" colspan="1">40 min</th>
                        <th align="center" rowspan="1" colspan="1">230 min</th>
                        <th align="center" rowspan="1" colspan="1">Day 1</th>
                        <th align="center" rowspan="1" colspan="1">Week 1 (repeats weekly)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="center" rowspan="4" colspan="1">Clinical state</td>
                        <td align="center" rowspan="1" colspan="1">HDRS24</td>
                        <td align="center" rowspan="1" colspan="1">m = 28.6, R = 16–43<break/>(29.3 ± 5.9)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">m = 19.5, R = 2–43<break/>(20.0 ± 9.7)</td>
                        <td align="center" rowspan="1" colspan="1">m = 20.5, R = 3–36<break/>(20.3 ± 8.3)</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">HDRS17</td>
                        <td align="center" rowspan="1" colspan="1">m = 21.5, R = 12–31<break/>(22.2 ± 4.6)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">m = 15.0, R = 2–32<break/>(15.2 ± 7.7)</td>
                        <td align="center" rowspan="1" colspan="1">m = 15.0, R = 2–30<break/>(16.0 ± 6.6)</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">POMS total</td>
                        <td align="center" rowspan="1" colspan="1">m = 90.5, R = 11–192<break/>(95.9 ± 37.4)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">m = 56.0, R = 1–175<break/>(60.3 ± 37.3)</td>
                        <td align="center" rowspan="1" colspan="1">m = 57.5, R = −13–164<break/>(61.3 ± 45.5)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">SSI</td>
                        <td align="center" rowspan="1" colspan="1">m = 14.0, R = 4–26<break/>(14.3 ± 6.3)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">m = 5.0, R = 0–20<break/>(5.0 ± 5.2)</td>
                        <td align="center" rowspan="1" colspan="1">m = 5.5, R = 0–21<break/>(6.1 ± 5.5)</td>
                        <td align="center" rowspan="1" colspan="1">m = 4.0, R = 0–24<break/>(5.3 ± 5.9)</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">Dissociative symptoms</td>
                        <td align="center" rowspan="1" colspan="1">CADSS</td>
                        <td align="center" rowspan="1" colspan="1">m = 1.0, R = 0–15<break/>(2.8 ± 3.8)</td>
                        <td align="center" rowspan="1" colspan="1">m = 17.0, R = 0–50<break/>(17.6 ± 13.5)</td>
                        <td align="center" rowspan="1" colspan="1">m = 0.0, R = 0–9<break/>(1.1 ± 2.2)</td>
                        <td align="center" rowspan="1" colspan="1">m = 0.0, R = 0–20<break/>(1.3 ± 3.6)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">Psychotic symptoms</td>
                        <td align="center" rowspan="1" colspan="1">BPRS</td>
                        <td align="center" rowspan="1" colspan="1">m = 0.0, R = 0–2<break/>(0.1 ± 0.3)</td>
                        <td align="center" rowspan="1" colspan="1">m = 0.0, R = 0–9<break/>(0.7 ± 1.8)</td>
                        <td align="center" rowspan="1" colspan="1">m = 0.0, R = 0<break/>(0.0 ± 0.0)</td>
                        <td align="center" rowspan="1" colspan="1">m = 0.0, R = 0–1<break/>(0.1 ± 0.2)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1Fn1">
                      <p>Abbreviations: BPRS, Brief Psychiatric Rating Scale; CADSS, Clinician-Administered Dissociative States Scale; HDRS17, 17-item Hamilton Depression Rating Scale; HDRS24, 24-item Hamilton Depression Rating Scale; POMS, Profile of Mood States total score; SSI, Scale for Suicidal Ideation.</p>
                    </fn>
                    <fn id="T1Fn2">
                      <p>Mean values and SDs are provided in parentheses.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s8">
                <title>Measures</title>
                <p>The CADSS measures the severity of dissociative symptoms with scores ranging from 0 to 92 (<xref rid="CIT0010" ref-type="bibr">Bremner et al., 1998</xref>). The positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS) includes the items for conceptual disorganization, grandiosity, hallucinations, and delusions, and scores range from 0 to 24 (<xref rid="CIT0039" ref-type="bibr">Overall and Gorham, 1962</xref>). The CADSS and BPRS were administered at baseline, 40 minutes, 230 minutes, and Day 1 post-injection. While CADSS and BPRS results were reported in the safety outcomes and adverse effects section of the primary study report (<xref rid="CIT0020" ref-type="bibr">Grunebaum et al., 2018</xref>), during the conduct of the trial, the scales were introduced neutrally to participants as questions about things people sometimes feel associated with the infusion.</p>
                <p>Clinical efficacy measures were the HDRS, Profile of Moods Scale (POMS), and SSI (<xref rid="CIT0022" ref-type="bibr">Hamilton, 1960</xref>; <xref rid="CIT0033" ref-type="bibr">McNair et al., 1981</xref>; <xref rid="CIT0005" ref-type="bibr">Beck et al., 1988</xref>). The clinician-rated SSI assesses the severity of suicidal ideation as the items rate wish to die, passive and active suicidal thoughts and behavior, duration and frequency of ideation, sense of control, deterrents, and preparatory acts. The self-rated POMS was designed to assess 6 dimensions of mood over shorter time periods than the HDRS and has subscales for anxiety, depression, anger, vigor, fatigue, and confusion (<xref rid="CIT0033" ref-type="bibr">McNair et al., 1981</xref>). POMS total mood disturbance scores were used for this exploratory analysis. The HDRS was administered at baseline, Day 1, and Weeks 1–6 after the ketamine injection, while the POMS and SSI were administered at baseline, 230 minutes, and Day 1 with the SSI also being administered at Weeks 1–6.</p>
                <p>A subset (n = 28) of the randomized ketamine group had immediate post-infusion blood samples drawn to measure plasma levels of ketamine and the primary and secondary metabolites, respectively, norketamine (NK) and dehydronorketamine (DHNK) (<xref rid="CIT0021" ref-type="bibr">Grunebaum et al., 2019</xref>).</p>
              </sec>
              <sec id="s9">
                <title>Statistical Approach</title>
                <p>Due to skewed, outlier-prone distribution in some measures and the relatively limited sample size, we used nonparametric statistics throughout the analysis and dichotomized the BPRS variable. Spearman correlations tested associations between post-infusion raw and change from baseline scores on CADSS, respectively, with change from baseline scores in clinical outcomes. Change scores for the clinical efficacy and CADSS measures were calculated by subtracting the baseline scores from the post-infusion scores (a negative value indicates a decrease). Mann-Whitney U tests examined associations between dichotomized BPRS scores, which were heavily zero-inflated, and clinical efficacy measures.</p>
                <p>Spearman correlations tested the association between ketamine and metabolite blood levels with post-infusion dissociative and psychotomimetic symptoms. Although rank-based nonparametric tests are little if at all impacted by the removal of outliers, we explored the effect of removing 1 extreme outlier from 1 NK correlation. Because this was an exploratory analysis, no covariates were adjusted for, nor was there a multiple testing correction. All tests were 2-tailed with a significance level set at .05. Effect sizes in the form of correlation coefficients, rather than significance levels, were of primary interest.</p>
              </sec>
            </sec>
            <sec id="s10">
              <title>RESULTS</title>
              <p>Baseline CADSS scores were positively correlated with baseline scores on the 24-item HDRS (rho = .51, n = 40, <italic toggle="yes">P ≤</italic> .001), 17-item HDRS (rho = .429, n = 40, <italic toggle="yes">P</italic> = .006), BPRS positive symptom subscale (rho = .35, n = 40, <italic toggle="yes">P</italic> = .029), and baseline POMS scores (rho = .32, n = 40, <italic toggle="yes">P</italic> = .042). However, baseline CADSS scores were not associated with baseline SSI scores (rho = .23, n = 40, <italic toggle="yes">P</italic> = .160). Dichotomized baseline BPRS scores were not correlated with baseline scores on the 24-item HDRS (n = 40, <italic toggle="yes">P</italic> = .785), 17-item HDRS (n = 40, <italic toggle="yes">P</italic> = .926), POMS (n = 40, <italic toggle="yes">P</italic> = .656), and SSI (n = 40, <italic toggle="yes">P</italic> = .926).</p>
              <p>The immediate post-infusion CADSS score (at 40 minutes) (<xref rid="T1" ref-type="table">Table 1</xref>; median = 17.0; mean = 17.63; SD = 13.55) was not associated with change in SSI score at 230 minutes (rho = −.12, n = 40, <italic toggle="yes">P</italic> = .482) or Day 1 (rho = .01, n = 40, <italic toggle="yes">P</italic> = .971). Similarly, the 40-minute CADSS score was not associated with baseline to Day 1 change in the 24-item HDRS (rho = .08, n = 40, <italic toggle="yes">P</italic> = .644) or POMS scores (rho = −.05, n = 40, <italic toggle="yes">P</italic> = .752). The 40-minute CADSS score was also not associated with the 17- or 24-item HDRS (<italic toggle="yes">P</italic> = .454 and <italic toggle="yes">P</italic> = .714, respectively) nor with the SSI score (<italic toggle="yes">P</italic> = .881) change from baseline at the Week 6 timepoint.</p>
              <p>The immediate post-infusion CADSS change scores (baseline score subtracted from score at 40 minutes) were also not associated with change in SSI at 230 minutes (rho = −.09, n = 40, <italic toggle="yes">P</italic> = .594), Day 1 (rho = .03, n = 40, <italic toggle="yes">P</italic> = .863), or Week 1 (rho = .02, n = 38, <italic toggle="yes">P</italic> = .885). The CADSS change score at 40 minutes was not associated with Baseline to Day 1 change in the 24-item HDRS (rho = .12, n = 40, <italic toggle="yes">P</italic> = .511) or POMS scores (rho = −.02, n = 40, <italic toggle="yes">P</italic> = .885).</p>
              <p>The 230-minute CADSS change score was associated with the change in POMS score at 230 minutes (<xref rid="F1" ref-type="fig">Figure 1</xref>; rho = .410, n = 39, <italic toggle="yes">P</italic> = .01) such that, compared with baseline, decreasing dissociative symptoms correlated moderately with less mood disturbance. All other post-infusion CADSS change scores were not related to changes in depression or suicidal ideation.</p>
              <fig position="float" id="F1">
                <label>Figure 1.</label>
                <caption>
                  <p>Scatter plot of relationship between change in dissociative symptoms (Clinician-Administered Dissociative States Scale [CADSS]) and change in Profile of Mood States (POMS) total scores at 230 minutes post-ketamine. <bold>Change in dissociative symptoms at 230 minutes are correlated with the change in total POMS 230 minute score (rho = .410, n = 39, <italic toggle="yes">P</italic> = 0.01).</bold></p>
                </caption>
                <graphic xlink:href="pyae017_fig1" position="float"/>
              </fig>
              <p>Post-infusion psychotomimetic symptoms using the BPRS positive symptom subscale (median = 0; mean = 0.68, SD = 1.80) were not associated with changes in any clinical outcomes (<italic toggle="yes">P</italic> &gt; .121) or blood levels of ketamine or metabolites (<italic toggle="yes">P</italic> &gt; .194).</p>
              <p>In the subgroup (n = 28) with blood levels, there was a trend-level, moderate-sized inverse correlation of NK with the CADSS Day 1 change score (<xref rid="F2" ref-type="fig">Figure 2</xref>; rho = −.36, n = 28, <italic toggle="yes">P</italic>  = .064). After removing 1 outlier with a CADSS Day 1 change score of 13, there was a stronger inverse correlation of NK with CADSS Day 1 change score (<xref rid="F3" ref-type="fig">Figure 3</xref>; rho = −.47, n = 27, <italic toggle="yes">P</italic> = .013). In other words, higher post-infusion NK was associated with greater decrease in dissociative symptoms from baseline to Day 1.</p>
              <fig position="float" id="F2">
                <label>Figure 2.</label>
                <caption>
                  <p>Scatter plot of relationship between immediate post-infusion plasma norketamine (NK) and change in dissociative symptoms (Clinician-Administered Dissociative States Scale [CADSS]) from baseline to Day 1. <bold>Immediate post-infusion norketamine (NK) levels are inversely correlated with the change in CADSS Day 1 score at trend level (rho = -.36, n = 28, <italic toggle="yes">P</italic> = .064).</bold></p>
                </caption>
                <graphic xlink:href="pyae017_fig2" position="float"/>
              </fig>
              <fig position="float" id="F3">
                <label>Figure 3.</label>
                <caption>
                  <p>Scatter plot of relationship between immediate post-infusion plasma norketamine (NK) and change in dissociative symptoms (Clinician-Administered Dissociative States Scale [CADSS]) from baseline to Day 1 with 1 outlier removed. <bold>Immediate post-infusion norketamine (NK) levels with no outlier are inversely correlated with the change in CADSS Day 1 score (rho = -.47, n = 27, <italic toggle="yes">P</italic> = .013).</bold></p>
                </caption>
                <graphic xlink:href="pyae017_fig3" position="float"/>
              </fig>
              <p>There was no correlation between DHNK and the change in CADSS scores at 40 minutes (rho = −.32, n = 28, <italic toggle="yes">P</italic>  = .093). No data points were identified as outliers. All other correlations of ketamine and metabolite blood levels with CADSS change scores at 40 minutes, 230 minutes, and Day 1 post-infusion were not significant (<italic toggle="yes">P</italic> &gt; .10).</p>
              <p>We found an association between DHNK and CADSS scores at 40 minutes (rho = .40, n = 28, <italic toggle="yes">P </italic>= .034), 230 minutes (rho = .46, n = 28, <italic toggle="yes">P </italic>= .014), and Day 1 (rho = .486, n = 26, <italic toggle="yes">P</italic> = .012).</p>
            </sec>
            <sec id="s11">
              <title>DISCUSSION</title>
              <p>We found associations at baseline between dissociative symptoms and measures of depression and mood disturbance but not with suicidal ideation. Before ketamine administration, individuals experiencing baseline dissociative symptoms reported more severe mood disturbances, depressive symptoms, and psychotic symptoms. These findings are consistent with recent studies that indicate a direct relationship between dissociative symptoms, depression, and psychosis (<xref rid="CIT0017" ref-type="bibr">Fung et al., 2020</xref>, <xref rid="CIT0018" ref-type="bibr">2022</xref>; <xref rid="CIT0027" ref-type="bibr">Longden et al., 2020</xref>; <xref rid="CIT0008" ref-type="bibr">Bertule et al., 2021</xref>). Baseline dissociative symptoms may be indicative of trauma-related comorbidity in depressed persons as dissociation is a common symptom of post-traumatic stress (<xref rid="CIT0041" ref-type="bibr">Powers et al., 2015</xref>).</p>
              <p>We did not find evidence of associations between ketamine’s acute and sub-acute dissociative effects and its antidepressant or anti-suicidal ideation actions. On the contrary, we found limited evidence at the 230-minute timepoint, suggesting that lower dissociative symptoms were associated with lower mood disturbance. This is consistent with the correlations we found of baseline CADSS scores with HDRS and POMS. Thus, we speculate the CADSS scale may be sensitive to severity of mood state. With the exception of the 230-minute timepoint, neither dissociative symptom scores nor their change from baseline were associated with a change in clinical outcomes (suicidal ideation, mood, and depression) from baseline to the post-infusion time points when ketamine’s therapeutic effects would typically be strongest (within 24 hours).</p>
              <p>Our findings add to previous studies that found no correlation between ketamine-induced dissociation and its therapeutic effect (<xref rid="CIT0047" ref-type="bibr">Valentine et al., 2011</xref>; <xref rid="CIT0002" ref-type="bibr">Acevedo-Diaz et al., 2020</xref>; <xref rid="CIT0034" ref-type="bibr">Milak et al., 2020</xref>; <xref rid="CIT0031" ref-type="bibr">Mathai et al., 2023</xref>). Taken together, these results suggest that ketamine’s acute dissociative effects may be more of an adverse effect rather than a mediator of therapeutic action.</p>
              <p>We did not find evidence that ketamine’s acute or sub-acute psychotomimetic effects are associated with its clinical efficacy. The positive symptom subscale of the BPRS was not related to clinical efficacy or ketamine and metabolite blood levels.</p>
              <p>Ketamine, which has a half-life of 2 hours (<xref rid="CIT0048" ref-type="bibr">White et al., 1985</xref>), undergoes metabolism in the liver. Ketamine is demethylated to become NK, which has a half-life of 5 hours (<xref rid="CIT0037" ref-type="bibr">Newcomer et al., 1999</xref>). NK is then metabolized into DHNK and 6 hydroxynorketamine metabolites (HNK) in addition to 2 hydroxyketamine metabolites (<xref rid="CIT0054" ref-type="bibr">Zarate et al., 2012</xref>; <xref rid="CIT0024" ref-type="bibr">Kamp et al., 2020</xref>). We found a trend-level association of higher plasma NK immediately post-infusion with a decrease in dissociative symptoms on Day 1. Preclinical data suggest that NK is about 20% to 60% as potent as ketamine, crosses the blood-brain barrier, and contributes to analgesic and psychotomimetic side effects (<xref rid="CIT0026" ref-type="bibr">Leung and Baillie, 1986</xref>). Thus, greater metabolism of the more potent parent compound to the metabolite may be associated with lower dissociative effects. A previous post hoc analysis, however, found that ketamine and NK were uniquely related to dissociation (Farmer et al., 2020).</p>
              <p>We also found positive associations between the metabolite DHNK and CADSS scores at 40 minutes, 230 minutes, and Day 1. This is partly consistent with our group’s prior work in an independent sample that found that ketamine, NK, and DHNK correlated with BPRS score but only in men (<xref rid="CIT0034" ref-type="bibr">Milak et al., 2020</xref>). Some research found a negative correlation of DHNK with BPRS symptoms at 40 minutes, but no association with CADSS was reported (<xref rid="CIT0054" ref-type="bibr">Zarate et al., 2012</xref>). Other research found no significant correlation between ketamine, NK, and DHNK blood levels, levels of dissociation, and positive psychotic symptoms (<xref rid="CIT0042" ref-type="bibr">Rodriguez et al., 2013</xref>). It is unclear how to interpret the association of DHNK with dissociative effects. Perhaps it may be related to DHNK having the longest plasma half-life of the metabolites, as it has been detected in volunteers after 6 to 10 days (<xref rid="CIT0023" ref-type="bibr">Hijazi et al., 2001</xref>; <xref rid="CIT0040" ref-type="bibr">Parkin et al., 2008</xref>). We previously reported an association of higher DHNK with less improvement in suicidal ideation ratings during 6-week post-infusion follow-up in this sample (<xref rid="CIT0021" ref-type="bibr">Grunebaum et al., 2019</xref>). The latter could suggest a negative clinical effect of this metabolite but requires further study.</p>
              <p>Different findings may be related to our study’s unipolar MDD sample as the Zarate et al. study also included BD, which was associated with higher DHNK levels (<xref rid="CIT0054" ref-type="bibr">Zarate et al., 2012</xref>). DHNK, followed by NK, inhibits acetylcholine-evoked currents in alpha7-nicotinic acetylcholine receptors, which may contribute to clinical efficacy (<xref rid="CIT0035" ref-type="bibr">Moaddel et al., 2013</xref>).</p>
              <p>We did not find an association between (2S, 6S; 2R, 6R)-HNK levels and ketamine’s dissociative effects at any post-injection time point. This finding is consistent with prior findings that (2R, 6R)-HNK does not inhibit the NMDA receptor (<xref rid="CIT0052" ref-type="bibr">Zanos et al., 2016</xref>; <xref rid="CIT0029" ref-type="bibr">Lumsden et al., 2019</xref>; <xref rid="CIT0016" ref-type="bibr">Farmer et al., 2020</xref>).</p>
              <p>Our study has limitations, including its post hoc design and modest sample size, though it is one of the larger and more rigorous ketamine trials in a suicidal sample. As other groups have noted, the CADSS was designed to identify PTSD-associated dissociation and may not be an ideal measure of drug-induced dissociative effects (<xref rid="CIT0003" ref-type="bibr">Ballard and Zarate, 2020</xref>). Future studies should consider using the Altered States of Consciousness Ratings Scale, which may be more relevant to drug-induced dissociation (<xref rid="CIT0020" ref-type="bibr">Grunebaum et al., 2018</xref>). Our blood level results are limited by the small subgroup sample size. The limitation of potential functional unblinding is common to all ketamine studies given the drug’s unique psychiatric effects (<xref rid="CIT0003" ref-type="bibr">Ballard and Zarate, 2020</xref>).</p>
              <p>Our study also did not include psychotherapy, which some data suggest may enhance therapeutic effects of ketamine (<xref rid="CIT0014" ref-type="bibr">Dakwar et al., 2019</xref>; <xref rid="CIT0050" ref-type="bibr">Wilkinson et al., 2021</xref>). It is suggested that cognitive-behavioral therapy may stabilize synaptic connections and improve long-term outcomes of ketamine treatment (<xref rid="CIT0050" ref-type="bibr">Wilkinson et al., 2021</xref>). Additionally, the dissociation triggered by ketamine might enhance patients’ ability to engage in psychotherapy by promoting a temporary pause from reality, relief from negativity, and an openness to new thoughts (<xref rid="CIT0015" ref-type="bibr">Dore et al., 2019</xref>). These dissociative experiences similarly reflect the subjective, psychedelic-type effects observed in psilocybin studies, such as mystical experiences, which have been explored for their relationship to therapeutic outcomes (<xref rid="CIT0019" ref-type="bibr">Griffiths et al., 2011</xref>).</p>
              <p>The conflicting literature underscores the need for more rigorous a priori study designs to determine the relationship between acute dissociative vs therapeutic effects of ketamine. Nonetheless, our results add to the data finding no evidence that acute dissociation or psychotomimetic effects are integral to ketamine’s antidepressant or anti-suicidal ideation therapeutic action.</p>
            </sec>
          </body>
          <back>
            <ack id="a1">
              <title>Acknowledgments</title>
              <p>The authors thank the staff of the NYSPI inpatient General Clinical Research Unit and the participants who contributed to this research.</p>
            </ack>
            <sec id="s12">
              <p>This work was supported by National Institute of Health (NIH) grant MH096784 (PI: Grunebaum).</p>
            </sec>
            <sec id="s13">
              <title>Interest Statement</title>
              <p>Drs Mann and Burke receive royalties from the Research Foundation for Mental Hygiene (RFMH) for commercial use of the C-SSRS which was not part of this work. Dr Galfalvy and her family own stocks in IBM, Inc. and in Illumina, Inc. Dr Keilp and his spouse own stock in Pfizer, Inc. and Zoetis, Inc. The other authors report no conflicts of interest.</p>
            </sec>
            <sec sec-type="data-availability" id="s14">
              <title>Data Availability</title>
              <p>Data underlying this article will be made available on request to the corresponding author.</p>
            </sec>
            <sec id="s15">
              <title>Author Statement</title>
              <p>All authors have made substantial contributions to the study design, data acquisition, analysis, interpretation, and/or drafting and editing of the manuscript. All authors have read and approved the submitted manuscript and are accountable for the accuracy and integrity of the work.</p>
            </sec>
            <sec id="s16">
              <title>Author Contributions</title>
              <p>Sumra Sajid (Resources [Lead], Software [Lead], Validation [Equal], Visualization [Equal], Writing—original draft [Lead], Writing—review and editing [Equal]), Hanga Galfalvy (Formal analysis [Equal], Software [Equal], Supervision [Supporting], Validation [Equal], Writing—review and editing [Equal]), John Keilp (Data curation [Equal], Formal analysis [Equal], Software [Equal], Visualization [Equal]), Ainsley Burke (Investigation [Equal], Methodology [Equal], Project administration [Equal]), John Mann (Conceptualization [Equal], Methodology [Equal], Validation [Equal], Writing—review and editing [Equal]), and Michael Grunebaum (Conceptualization [Lead], Data curation [Equal], Formal analysis [Equal], Funding acquisition [Lead], Investigation [Lead], Methodology [Lead], Project administration [Lead], Resources [Equal], Software [Equal], Supervision [Lead], Validation [Equal], Visualization [Equal], Writing—review and editing [Lead]).</p>
            </sec>
            <ref-list id="r1">
              <title>References</title>
              <ref id="CIT0001">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdallah</surname><given-names>CG</given-names></string-name>, <string-name><surname>De Feyter</surname><given-names>HM</given-names></string-name>, <string-name><surname>Averill</surname><given-names>LA</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name><surname>Averill</surname><given-names>CL</given-names></string-name>, <string-name><surname>Chowdhury</surname><given-names>GMI</given-names></string-name>, <string-name><surname>Purohit</surname><given-names>P</given-names></string-name>, <string-name><surname>de Graaf</surname><given-names>RA</given-names></string-name>, <string-name><surname>Esterlis</surname><given-names>I</given-names></string-name>, <string-name><surname>Juchem</surname><given-names>C</given-names></string-name>, <string-name><surname>Pittman</surname><given-names>BP</given-names></string-name>, <string-name><surname>Krystal</surname><given-names>JH</given-names></string-name>, <string-name><surname>Rothman</surname><given-names>DL</given-names></string-name>, <string-name><surname>Sanacora</surname><given-names>G</given-names></string-name>, <string-name><surname>Mason</surname><given-names>GF</given-names></string-name></person-group> (<year>2018</year>) <article-title>The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects</article-title>. <source>Neuropsychopharmacology</source><volume>43</volume>:<fpage>2154</fpage>–<lpage>2160</lpage>.<pub-id pub-id-type="pmid">29977074</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0002">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Acevedo-Diaz</surname><given-names>EE</given-names></string-name>, <string-name><surname>Cavanaugh</surname><given-names>GW</given-names></string-name>, <string-name><surname>Greenstein</surname><given-names>D</given-names></string-name>, <string-name><surname>Kraus</surname><given-names>C</given-names></string-name>, <string-name><surname>Kadriu</surname><given-names>B</given-names></string-name>, <string-name><surname>Park</surname><given-names>L</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></string-name></person-group> (<year>2020</year>) <article-title>Can ‘floating’ predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression</article-title>. <source>J Psychiatr Res</source><volume>130</volume>:<fpage>280</fpage>–<lpage>285</lpage>.<pub-id pub-id-type="pmid">32861983</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0003">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ballard</surname><given-names>ED</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names></string-name></person-group> (<year>2020</year>) <article-title>The role of dissociation in ketamine’s antidepressant effects</article-title>. <source>Nat Commun</source><volume>11</volume>:<fpage>6431</fpage>.<pub-id pub-id-type="pmid">33353946</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0004">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beck</surname><given-names>AT</given-names></string-name>, <string-name><surname>Kovacs</surname><given-names>M</given-names></string-name>, <string-name><surname>Weissman</surname><given-names>A</given-names></string-name></person-group> (<year>1979</year>) <article-title>Assessment of suicidal intention: the Scale for Suicide Ideation</article-title>. <source>J Consult Clin Psychol</source><volume>47</volume>:<fpage>343</fpage>–<lpage>352</lpage>.<pub-id pub-id-type="pmid">469082</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0005">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beck</surname><given-names>AT</given-names></string-name>, <string-name><surname>Steer</surname><given-names>RA</given-names></string-name>, <string-name><surname>Ranieri</surname><given-names>WF</given-names></string-name></person-group> (<year>1988</year>) <article-title>Scale for suicide ideation: psychometric properties of a self-report version</article-title>. <source>J Clin Psychol</source><volume>44</volume>:<fpage>499</fpage>–<lpage>505</lpage>.<pub-id pub-id-type="pmid">3170753</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0006">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berman</surname><given-names>RM</given-names></string-name>, <string-name><surname>Cappiello</surname><given-names>A</given-names></string-name>, <string-name><surname>Anand</surname><given-names>A</given-names></string-name>, <string-name><surname>Oren</surname><given-names>DA</given-names></string-name>, <string-name><surname>Heninger</surname><given-names>GR</given-names></string-name>, <string-name><surname>Charney</surname><given-names>DS</given-names></string-name>, <string-name><surname>Krystal</surname><given-names>JH</given-names></string-name></person-group> (<year>2000</year>) <article-title>Antidepressant effects of ketamine in depressed patients</article-title>. <source>Biol Psychiatry</source><volume>47</volume>:<fpage>351</fpage>–<lpage>354</lpage>.<pub-id pub-id-type="pmid">10686270</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0007">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernstein</surname><given-names>EM</given-names></string-name>, <string-name><surname>Putnam</surname><given-names>FW</given-names></string-name></person-group> (<year>1986</year>) <article-title>Development, reliability, and validity of a dissociation scale</article-title>. <source>J Nerv Ment Dis</source><volume>174</volume>:<fpage>727</fpage>–<lpage>735</lpage>.<pub-id pub-id-type="pmid">3783140</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0008">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bertule</surname><given-names>M</given-names></string-name>, <string-name><surname>Sebre</surname><given-names>SB</given-names></string-name>, <string-name><surname>Kolesovs</surname><given-names>A</given-names></string-name></person-group> (<year>2021</year>) <article-title>Childhood abuse experiences, depression and dissociation symptoms in relation to suicide attempts and suicidal ideation</article-title>. <source>J Trauma Dissociation</source><volume>22</volume>:<fpage>598</fpage>–<lpage>614</lpage>.<pub-id pub-id-type="pmid">33427600</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0009">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyer</surname><given-names>SM</given-names></string-name>, <string-name><surname>Caplan</surname><given-names>JE</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>LK</given-names></string-name></person-group> (<year>2022</year>) <article-title>Trauma-related dissociation and the dissociative disorders: neglected symptoms with severe public health consequences</article-title>. <source>Dela J Public Health</source><volume>8</volume>:<fpage>78</fpage>–<lpage>84</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0010">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bremner</surname><given-names>JD</given-names></string-name>, <string-name><surname>Krystal</surname><given-names>JH</given-names></string-name>, <string-name><surname>Putnam</surname><given-names>FW</given-names></string-name>, <string-name><surname>Southwick</surname><given-names>SM</given-names></string-name>, <string-name><surname>Marmar</surname><given-names>C</given-names></string-name>, <string-name><surname>Charney</surname><given-names>DS</given-names></string-name>, <string-name><surname>Mazure</surname><given-names>CM</given-names></string-name></person-group> (<year>1998</year>) <article-title>Measurement of dissociative States with the Clinician-Administered Dissociative States Scale (CADSS)</article-title>. <source>J Trauma Stress</source><volume>11</volume>:<fpage>125</fpage>–<lpage>136</lpage>.<pub-id pub-id-type="pmid">9479681</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0011">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butler</surname><given-names>LD</given-names></string-name></person-group> (<year>2006</year>) <article-title>Normative dissociation</article-title>. <source>Psychiatr Clin North Am</source><volume>29</volume>:<fpage>45</fpage>–<lpage>62, viii</lpage>.<pub-id pub-id-type="pmid">16530586</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0012">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>MH</given-names></string-name>, <string-name><surname>Lin</surname><given-names>WC</given-names></string-name>, <string-name><surname>Wu</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Bai</surname><given-names>YM</given-names></string-name>, <string-name><surname>Li</surname><given-names>CT</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Hong</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Tu</surname><given-names>PC</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>CM</given-names></string-name>, <string-name><surname>Su</surname><given-names>TP</given-names></string-name></person-group> (<year>2020</year>) <article-title>Happiness during low-dose ketamine infusion predicts treatment response: reexploring the adjunctive ketamine study of taiwanese patients with treatment-resistant depression</article-title>. <source>J Clin Psychiatry</source><volume>81</volume>:<fpage>20m13232</fpage>.</mixed-citation>
              </ref>
              <ref id="CIT0013">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Correia-Melo</surname><given-names>FS</given-names></string-name>, <string-name><surname>Argolo</surname><given-names>FC</given-names></string-name>, <string-name><surname>Araújo-de-Freitas</surname><given-names>L</given-names></string-name>, <string-name><surname>Leal</surname><given-names>GC</given-names></string-name>, <string-name><surname>Kapczinski</surname><given-names>F</given-names></string-name>, <string-name><surname>Lacerda</surname><given-names>AL</given-names></string-name>, <string-name><surname>Quarantini</surname><given-names>LC</given-names></string-name></person-group> (<year>2017</year>) <article-title>Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review</article-title>. <source>Neuropsychiatr Dis Treat</source><volume>13</volume>:<fpage>1627</fpage>–<lpage>1632</lpage>.<pub-id pub-id-type="pmid">28790825</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0014">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dakwar</surname><given-names>E</given-names></string-name>, <string-name><surname>Nunes</surname><given-names>EV</given-names></string-name>, <string-name><surname>Hart</surname><given-names>CL</given-names></string-name>, <string-name><surname>Foltin</surname><given-names>RW</given-names></string-name>, <string-name><surname>Mathew</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>KM</given-names></string-name>, <string-name><surname>Choi</surname><given-names>CJJ</given-names></string-name>, <string-name><surname>Basaraba</surname><given-names>CN</given-names></string-name>, <string-name><surname>Pavlicova</surname><given-names>M</given-names></string-name>, <string-name><surname>Levin</surname><given-names>FR</given-names></string-name></person-group> (<year>2019</year>) <article-title>A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial</article-title>. <source>Am J Psychiatry</source><volume>176</volume>:<fpage>923</fpage>–<lpage>930</lpage>.<pub-id pub-id-type="pmid">31230464</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0015">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dore</surname><given-names>J</given-names></string-name>, <string-name><surname>Turnipseed</surname><given-names>B</given-names></string-name>, <string-name><surname>Dwyer</surname><given-names>S</given-names></string-name>, <string-name><surname>Turnipseed</surname><given-names>A</given-names></string-name>, <string-name><surname>Andries</surname><given-names>J</given-names></string-name>, <string-name><surname>Ascani</surname><given-names>G</given-names></string-name>, <string-name><surname>Monnette</surname><given-names>C</given-names></string-name>, <string-name><surname>Huidekoper</surname><given-names>A</given-names></string-name>, <string-name><surname>Strauss</surname><given-names>N</given-names></string-name>, <string-name><surname>Wolfson</surname><given-names>P</given-names></string-name></person-group> (<year>2019</year>) <article-title>Ketamine Assisted Psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy</article-title>. <source>J Psychoactive Drugs</source><volume>51</volume>:<fpage>189</fpage>–<lpage>198</lpage>.<pub-id pub-id-type="pmid">30917760</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0016">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname><given-names>CA</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>JR</given-names></string-name>, <string-name><surname>Moaddel</surname><given-names>R</given-names></string-name>, <string-name><surname>George</surname><given-names>J</given-names></string-name>, <string-name><surname>Adeojo</surname><given-names>L</given-names></string-name>, <string-name><surname>Lovett</surname><given-names>J</given-names></string-name>, <string-name><surname>Nugent</surname><given-names>AC</given-names></string-name>, <string-name><surname>Kadriu</surname><given-names>B</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>P</given-names></string-name>, <string-name><surname>Gould</surname><given-names>TD</given-names></string-name>, <string-name><surname>Park</surname><given-names>LT</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names>, <suffix>Jr</suffix></string-name></person-group> (<year>2020</year>).<article-title> Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression</article-title>. <source>Neuropsychopharmacology</source><volume>45</volume>:<fpage>1398</fpage>–<lpage>1404</lpage>.<pub-id pub-id-type="pmid">32252062</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0017">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fung</surname><given-names>HW</given-names></string-name>, <string-name><surname>Chan</surname><given-names>C</given-names></string-name>, <string-name><surname>Ross</surname><given-names>CA</given-names></string-name>, <string-name><surname>Choi</surname><given-names>TM</given-names></string-name></person-group> (<year>2020</year>) <article-title>A preliminary investigation of depression in people with pathological dissociation</article-title>. <source>J Trauma Dissociation</source><volume>21</volume>:<fpage>594</fpage>–<lpage>608</lpage>.<pub-id pub-id-type="pmid">32397920</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0018">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fung</surname><given-names>HW</given-names></string-name>, <string-name><surname>Chien</surname><given-names>WT</given-names></string-name>, <string-name><surname>Lam</surname><given-names>SKK</given-names></string-name>, <string-name><surname>Ross</surname><given-names>CA</given-names></string-name></person-group> (<year>2022</year>) <article-title>Prevalence and correlates of dissociative symptoms among people with depression</article-title>. <source>J Psychiatr Res</source><volume>154</volume>:<fpage>132</fpage>–<lpage>138</lpage>.<pub-id pub-id-type="pmid">35933857</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0019">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Griffiths</surname><given-names>RR</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>MW</given-names></string-name>, <string-name><surname>Richards</surname><given-names>WA</given-names></string-name>, <string-name><surname>Richards</surname><given-names>BD</given-names></string-name>, <string-name><surname>McCann</surname><given-names>U</given-names></string-name>, <string-name><surname>Jesse</surname><given-names>R</given-names></string-name></person-group> (<year>2011</year>) <article-title>Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects</article-title>. <source>Psychopharmacology (Berl)</source><volume>218</volume>:<fpage>649</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">21674151</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0020">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grunebaum</surname><given-names>MF</given-names></string-name>, <string-name><surname>Galfalvy</surname><given-names>HC</given-names></string-name>, <string-name><surname>Choo</surname><given-names>TH</given-names></string-name>, <string-name><surname>Keilp</surname><given-names>JG</given-names></string-name>, <string-name><surname>Moitra</surname><given-names>VK</given-names></string-name>, <string-name><surname>Parris</surname><given-names>MS</given-names></string-name>, <string-name><surname>Marver</surname><given-names>JE</given-names></string-name>, <string-name><surname>Burke</surname><given-names>AK</given-names></string-name>, <string-name><surname>Milak</surname><given-names>MS</given-names></string-name>, <string-name><surname>Sublette</surname><given-names>ME</given-names></string-name>, <string-name><surname>Oquendo</surname><given-names>MA</given-names></string-name>, <string-name><surname>Mann</surname><given-names>JJ</given-names></string-name></person-group> (<year>2018</year>) <article-title>Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial</article-title>. <source>Am J Psychiatry</source><volume>175</volume>:<fpage>327</fpage>–<lpage>335</lpage>.<pub-id pub-id-type="pmid">29202655</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0021">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grunebaum</surname><given-names>MF</given-names></string-name>, <string-name><surname>Galfalvy</surname><given-names>HC</given-names></string-name>, <string-name><surname>Choo</surname><given-names>TH</given-names></string-name>, <string-name><surname>Parris</surname><given-names>MS</given-names></string-name>, <string-name><surname>Burke</surname><given-names>AK</given-names></string-name>, <string-name><surname>Suckow</surname><given-names>RF</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>TB</given-names></string-name>, <string-name><surname>Mann</surname><given-names>JJ</given-names></string-name></person-group> (<year>2019</year>) <article-title>Ketamine metabolite pilot study in a suicidal depression trial</article-title>. <source>J Psychiatr Res</source><volume>117</volume>:<fpage>129</fpage>–<lpage>134</lpage>.<pub-id pub-id-type="pmid">31415914</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0022">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamilton</surname><given-names>M</given-names></string-name></person-group> (<year>1960</year>) <article-title>A rating scale for depression</article-title>. <source>J Neurol Neurosurg Psychiatry</source><volume>23</volume>:<fpage>56</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">14399272</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0023">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hijazi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Bolon</surname><given-names>M</given-names></string-name>, <string-name><surname>Boulieu</surname><given-names>R</given-names></string-name></person-group> (<year>2001</year>) <article-title>Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples</article-title>. <source>Clin Chem</source><volume>47</volume>:<fpage>1713</fpage>–<lpage>1715</lpage>.<pub-id pub-id-type="pmid">11514412</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0024">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kamp</surname><given-names>J</given-names></string-name>, <string-name><surname>Jonkman</surname><given-names>K</given-names></string-name>, <string-name><surname>van Velzen</surname><given-names>M</given-names></string-name>, <string-name><surname>Aarts</surname><given-names>L</given-names></string-name>, <string-name><surname>Niesters</surname><given-names>M</given-names></string-name>, <string-name><surname>Dahan</surname><given-names>A</given-names></string-name>, <string-name><surname>Olofsen</surname><given-names>E</given-names></string-name></person-group> (<year>2020</year>) <article-title>Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis</article-title>. <source>Br J Anaesth</source><volume>125</volume>:<fpage>750</fpage>–<lpage>761</lpage>.<pub-id pub-id-type="pmid">32838982</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0025">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krystal</surname><given-names>JH</given-names></string-name>, <string-name><surname>Karper</surname><given-names>LP</given-names></string-name>, <string-name><surname>Seibyl</surname><given-names>JP</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>GK</given-names></string-name>, <string-name><surname>Delaney</surname><given-names>R</given-names></string-name>, <string-name><surname>Bremner</surname><given-names>JD</given-names></string-name>, <string-name><surname>Heninger</surname><given-names>GR</given-names></string-name>, <string-name><surname>Bowers</surname><given-names>MB</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Charney</surname><given-names>DS</given-names></string-name></person-group> (<year>1994</year>) <article-title>Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>. <source>Arch Gen Psychiatry</source><volume>51</volume>:<fpage>199</fpage>–<lpage>214</lpage>.<pub-id pub-id-type="pmid">8122957</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0026">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leung</surname><given-names>LY</given-names></string-name>, <string-name><surname>Baillie</surname><given-names>TA</given-names></string-name></person-group> (<year>1986</year>) <article-title>Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine</article-title>. <source>J Med Chem</source><volume>29</volume>:<fpage>2396</fpage>–<lpage>2399</lpage>.<pub-id pub-id-type="pmid">3783598</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0027">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Longden</surname><given-names>E</given-names></string-name>, <string-name><surname>Branitsky</surname><given-names>A</given-names></string-name>, <string-name><surname>Moskowitz</surname><given-names>A</given-names></string-name>, <string-name><surname>Berry</surname><given-names>K</given-names></string-name>, <string-name><surname>Bucci</surname><given-names>S</given-names></string-name>, <string-name><surname>Varese</surname><given-names>F</given-names></string-name></person-group> (<year>2020</year>) <article-title>The relationship between dissociation and symptoms of psychosis: a meta-analysis</article-title>. <source>Schizophr Bull</source><volume>46</volume>:<fpage>1104</fpage>–<lpage>1113</lpage>.<pub-id pub-id-type="pmid">32251520</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0028">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luckenbaugh</surname><given-names>DA</given-names></string-name>, <string-name><surname>Niciu</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ionescu</surname><given-names>DF</given-names></string-name>, <string-name><surname>Nolan</surname><given-names>NM</given-names></string-name>, <string-name><surname>Richards</surname><given-names>EM</given-names></string-name>, <string-name><surname>Brutsche</surname><given-names>NE</given-names></string-name>, <string-name><surname>Guevara</surname><given-names>S</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names></string-name></person-group> (<year>2014</year>) <article-title>Do the dissociative side effects of ketamine mediate its antidepressant effects</article-title>? <source>J Affect Disord</source><volume>159</volume>:<fpage>56</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">24679390</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0029">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lumsden</surname><given-names>EW</given-names></string-name></person-group>, <etal>et al</etal> (<year>2019</year>) <article-title>Antidepressant-relevant concentrations of the ketamine metabolite (2<italic toggle="yes">R</italic>,6<italic toggle="yes">R</italic>)-hydroxynorketamine do not block NMDA receptor function</article-title>. <source>Proc Natl Acad Sci USA</source><volume>116</volume>:<fpage>5160</fpage>–<lpage>5169</lpage>.<pub-id pub-id-type="pmid">30796190</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0030">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ly</surname><given-names>C</given-names></string-name>, <string-name><surname>Greb</surname><given-names>AC</given-names></string-name>, <string-name><surname>Cameron</surname><given-names>LP</given-names></string-name>, <string-name><surname>Wong</surname><given-names>JM</given-names></string-name>, <string-name><surname>Barragan</surname><given-names>EV</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>PC</given-names></string-name>, <string-name><surname>Burbach</surname><given-names>KF</given-names></string-name>, <string-name><surname>Soltanzadeh Zarandi</surname><given-names>S</given-names></string-name>, <string-name><surname>Sood</surname><given-names>A</given-names></string-name>, <string-name><surname>Paddy</surname><given-names>MR</given-names></string-name>, <string-name><surname>Duim</surname><given-names>WC</given-names></string-name>, <string-name><surname>Dennis</surname><given-names>MY</given-names></string-name>, <string-name><surname>McAllister</surname><given-names>AK</given-names></string-name>, <string-name><surname>Ori-McKenney</surname><given-names>KM</given-names></string-name>, <string-name><surname>Gray</surname><given-names>JA</given-names></string-name>, <string-name><surname>Olson</surname><given-names>DE</given-names></string-name></person-group> (<year>2018</year>) <article-title>Psychedelics Promote Structural and Functional Neural Plasticity</article-title>. <source>Cell Reports</source><volume>23</volume>:<fpage>3170</fpage>–<lpage>3182</lpage>.<pub-id pub-id-type="pmid">29898390</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0031">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mathai</surname><given-names>DS</given-names></string-name>, <string-name><surname>Nayak</surname><given-names>SM</given-names></string-name>, <string-name><surname>Yaden</surname><given-names>DB</given-names></string-name>, <string-name><surname>Garcia-Romeu</surname><given-names>A</given-names></string-name></person-group> (<year>2023</year>) <article-title>Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine</article-title>. <source>Psychopharmacology (Berl)</source><volume>240</volume>:<fpage>827</fpage>–<lpage>836</lpage>.<pub-id pub-id-type="pmid">36729145</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matveychuk</surname><given-names>D</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>RK</given-names></string-name>, <string-name><surname>Swainson</surname><given-names>J</given-names></string-name>, <string-name><surname>Khullar</surname><given-names>A</given-names></string-name>, <string-name><surname>MacKay</surname><given-names>MA</given-names></string-name>, <string-name><surname>Baker</surname><given-names>GB</given-names></string-name>, <string-name><surname>Dursun</surname><given-names>SM</given-names></string-name></person-group> (<year>2020</year>) <article-title>Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers</article-title>. <source>Ther Adv Psychopharmacol</source><volume>10</volume>:</mixed-citation>
              </ref>
              <ref id="CIT0033">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>McNair</surname><given-names>DM</given-names></string-name>, <string-name><surname>Lorr</surname><given-names>M</given-names></string-name>, <string-name><surname>Droppleman</surname><given-names>LF.</given-names></string-name></person-group> (<year>1981</year>). <source>Manual for the Profile of Mood States</source>. <publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Educational and Industrial Testing Service</publisher-name>.</mixed-citation>
              </ref>
              <ref id="CIT0034">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Milak</surname><given-names>MS</given-names></string-name>, <string-name><surname>Rashid</surname><given-names>R</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Z</given-names></string-name>, <string-name><surname>Kegeles</surname><given-names>LS</given-names></string-name>, <string-name><surname>Grunebaum</surname><given-names>MF</given-names></string-name>, <string-name><surname>Ogden</surname><given-names>RT</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name><surname>Mulhern</surname><given-names>ST</given-names></string-name>, <string-name><surname>Suckow</surname><given-names>RF</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>TB</given-names></string-name>, <string-name><surname>Keilp</surname><given-names>JG</given-names></string-name>, <string-name><surname>Mao</surname><given-names>X</given-names></string-name>, <string-name><surname>Shungu</surname><given-names>DC</given-names></string-name>, <string-name><surname>Mann</surname><given-names>JJ</given-names></string-name></person-group> (<year>2020</year>) <article-title>Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial</article-title>. <source>JAMA Netw Open</source><volume>3</volume>:<fpage>e2013211</fpage>.<pub-id pub-id-type="pmid">32785636</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0035">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moaddel</surname><given-names>R</given-names></string-name>, <string-name><surname>Abdrakhmanova</surname><given-names>G</given-names></string-name>, <string-name><surname>Kozak</surname><given-names>J</given-names></string-name>, <string-name><surname>Jozwiak</surname><given-names>K</given-names></string-name>, <string-name><surname>Toll</surname><given-names>L</given-names></string-name>, <string-name><surname>Jimenez</surname><given-names>L</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>A</given-names></string-name>, <string-name><surname>Tran</surname><given-names>T</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names></string-name>, <string-name><surname>Wainer</surname><given-names>IW</given-names></string-name></person-group> (<year>2013</year>) <article-title>Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors</article-title>. <source>Eur J Pharmacol</source><volume>698</volume>:<fpage>228</fpage>–<lpage>234</lpage>.<pub-id pub-id-type="pmid">23183107</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0036">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murrough</surname><given-names>JW</given-names></string-name>, <string-name><surname>Perez</surname><given-names>AM</given-names></string-name>, <string-name><surname>Pillemer</surname><given-names>S</given-names></string-name>, <string-name><surname>Stern</surname><given-names>J</given-names></string-name>, <string-name><surname>Parides</surname><given-names>MK</given-names></string-name>, <string-name><surname>aan het Rot</surname><given-names>M</given-names></string-name>, <string-name><surname>Collins</surname><given-names>KA</given-names></string-name>, <string-name><surname>Mathew</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Charney</surname><given-names>DS</given-names></string-name>, <string-name><surname>Iosifescu</surname><given-names>DV</given-names></string-name></person-group> (<year>2013</year>) <article-title>Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression</article-title>. <source>Biol Psychiatry</source><volume>74</volume>:<fpage>250</fpage>–<lpage>256</lpage>.<pub-id pub-id-type="pmid">22840761</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0037">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Newcomer</surname><given-names>JW</given-names></string-name>, <string-name><surname>Farber</surname><given-names>NB</given-names></string-name>, <string-name><surname>Jevtovic-Todorovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Selke</surname><given-names>G</given-names></string-name>, <string-name><surname>Melson</surname><given-names>AK</given-names></string-name>, <string-name><surname>Hershey</surname><given-names>T</given-names></string-name>, <string-name><surname>Craft</surname><given-names>S</given-names></string-name>, <string-name><surname>Olney</surname><given-names>JW</given-names></string-name></person-group> (<year>1999</year>) <article-title>Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis</article-title>. <source>Neuropsychopharmacology</source><volume>20</volume>:<fpage>106</fpage>–<lpage>118</lpage>.<pub-id pub-id-type="pmid">9885791</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0038">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niciu</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Shovestul</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Jaso</surname><given-names>BA</given-names></string-name>, <string-name><surname>Farmer</surname><given-names>C</given-names></string-name>, <string-name><surname>Luckenbaugh</surname><given-names>DA</given-names></string-name>, <string-name><surname>Brutsche</surname><given-names>NE</given-names></string-name>, <string-name><surname>Park</surname><given-names>LT</given-names></string-name>, <string-name><surname>Ballard</surname><given-names>ED</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></string-name></person-group> (<year>2018</year>) <article-title>Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression</article-title>. <source>J Affect Disord</source><volume>232</volume>:<fpage>310</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">29501990</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0039">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Overall</surname><given-names>JE</given-names></string-name>, <string-name><surname>Gorham</surname><given-names>DR</given-names></string-name></person-group> (<year>1962</year>) <article-title>The brief psychiatric rating scale</article-title>. <source>Psychol Rep</source><volume>10</volume>:<fpage>799</fpage>–<lpage>812</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0040">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parkin</surname><given-names>MC</given-names></string-name>, <string-name><surname>Turfus</surname><given-names>SC</given-names></string-name>, <string-name><surname>Smith</surname><given-names>NW</given-names></string-name>, <string-name><surname>Halket</surname><given-names>JM</given-names></string-name>, <string-name><surname>Braithwaite</surname><given-names>RA</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>SP</given-names></string-name>, <string-name><surname>Osselton</surname><given-names>MD</given-names></string-name>, <string-name><surname>Cowan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Kicman</surname><given-names>AT</given-names></string-name></person-group> (<year>2008</year>) <article-title>Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source><volume>876</volume>:<fpage>137</fpage>–<lpage>142</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0041">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Powers</surname><given-names>A</given-names></string-name>, <string-name><surname>Cross</surname><given-names>D</given-names></string-name>, <string-name><surname>Fani</surname><given-names>N</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>B</given-names></string-name></person-group> (<year>2015</year>) <article-title>PTSD, emotion dysregulation, and dissociative symptoms in a highly traumatized sample</article-title>. <source>J Psychiatr Res</source><volume>61</volume>:<fpage>174</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">25573648</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0042">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodriguez</surname><given-names>CI</given-names></string-name>, <string-name><surname>Kegeles</surname><given-names>LS</given-names></string-name>, <string-name><surname>Levinson</surname><given-names>A</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T</given-names></string-name>, <string-name><surname>Marcus</surname><given-names>SM</given-names></string-name>, <string-name><surname>Vermes</surname><given-names>D</given-names></string-name>, <string-name><surname>Flood</surname><given-names>P</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>HB</given-names></string-name></person-group> (<year>2013</year>) <article-title>Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept</article-title>. <source>Neuropsychopharmacology</source><volume>38</volume>:<fpage>2475</fpage>–<lpage>2483</lpage>.<pub-id pub-id-type="pmid">23783065</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0043">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Rosenbaum</surname><given-names>SB</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>V</given-names></string-name>, <string-name><surname>Patel</surname><given-names>P</given-names></string-name>, <string-name><surname>Palacios</surname><given-names>JL.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Ketamine</article-title>. In <source>StatPearls</source>. <publisher-name>StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC</publisher-name>, <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470357/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK470357/</ext-link>. <comment>Accessed 20 Oct. 2023</comment>.</mixed-citation>
              </ref>
              <ref id="CIT0044">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Şar</surname><given-names>V</given-names></string-name></person-group> (<year>2014</year>) <article-title>The many faces of dissociation: opportunities for innovative research in psychiatry</article-title>. <source>Clin Psychopharmacol Neurosci</source><volume>12</volume>:<fpage>171</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">25598819</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0045">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stocker</surname><given-names>K</given-names></string-name>, <string-name><surname>Hasler</surname><given-names>G</given-names></string-name>, <string-name><surname>Hartmann</surname><given-names>M</given-names></string-name></person-group> (<year>2019</year>) <article-title>The altered-state-of-consciousness (ASC) aspect of a feeling of lightness is reported to be associated with antidepressant benefits by depressed individuals receiving ketamine infusions: A systematic analysis of internet video testimonials</article-title>. <source>Psychother Psychosom</source><volume>88</volume>:<fpage>182</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">30884489</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0046">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Studerus</surname><given-names>E</given-names></string-name>, <string-name><surname>Gamma</surname><given-names>A</given-names></string-name>, <string-name><surname>Vollenweider</surname><given-names>FX</given-names></string-name></person-group> (<year>2010</year>) <article-title>Psychometric evaluation of the altered states of Consciousness Rating Scale (OAV)</article-title>. <source>PLoS One</source><volume>5</volume>:<fpage>e12412</fpage>.<pub-id pub-id-type="pmid">20824211</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0047">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Valentine</surname><given-names>GW</given-names></string-name>, <string-name><surname>Mason</surname><given-names>GF</given-names></string-name>, <string-name><surname>Gomez</surname><given-names>R</given-names></string-name>, <string-name><surname>Fasula</surname><given-names>M</given-names></string-name>, <string-name><surname>Watzl</surname><given-names>J</given-names></string-name>, <string-name><surname>Pittman</surname><given-names>B</given-names></string-name>, <string-name><surname>Krystal</surname><given-names>JH</given-names></string-name>, <string-name><surname>Sanacora</surname><given-names>G</given-names></string-name></person-group> (<year>2011</year>) <article-title>The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS</article-title>. <source>Psychiatry Res</source><volume>191</volume>:<fpage>122</fpage>–<lpage>127</lpage>.<pub-id pub-id-type="pmid">21232924</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0048">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>White</surname><given-names>PF</given-names></string-name>, <string-name><surname>Schüttler</surname><given-names>J</given-names></string-name>, <string-name><surname>Shafer</surname><given-names>A</given-names></string-name>, <string-name><surname>Stanski</surname><given-names>DR</given-names></string-name>, <string-name><surname>Horai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Trevor</surname><given-names>AJ</given-names></string-name></person-group> (<year>1985</year>) <article-title>Comparative pharmacology of the ketamine isomers. Studies in volunteers</article-title>. <source>Br J Anaesth</source><volume>57</volume>:<fpage>197</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">3970799</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0049">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilkinson</surname><given-names>ST</given-names></string-name>, <string-name><surname>Ballard</surname><given-names>ED</given-names></string-name>, <string-name><surname>Bloch</surname><given-names>MH</given-names></string-name>, <string-name><surname>Mathew</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Murrough</surname><given-names>JW</given-names></string-name>, <string-name><surname>Feder</surname><given-names>A</given-names></string-name>, <string-name><surname>Sos</surname><given-names>P</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr.</suffix></string-name>, <string-name><surname>Sanacora</surname><given-names>G</given-names></string-name></person-group> (<year>2018</year>) <article-title>The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis</article-title>. <source>Am J Psychiatry</source><volume>175</volume>:<fpage>150</fpage>–<lpage>158</lpage>.<pub-id pub-id-type="pmid">28969441</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0050">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilkinson</surname><given-names>ST</given-names></string-name>, <string-name><surname>Rhee</surname><given-names>TG</given-names></string-name>, <string-name><surname>Joormann</surname><given-names>J</given-names></string-name>, <string-name><surname>Webler</surname><given-names>R</given-names></string-name>, <string-name><surname>Ortiz Lopez</surname><given-names>M</given-names></string-name>, <string-name><surname>Kitay</surname><given-names>B</given-names></string-name>, <string-name><surname>Fasula</surname><given-names>M</given-names></string-name>, <string-name><surname>Elder</surname><given-names>C</given-names></string-name>, <string-name><surname>Fenton</surname><given-names>L</given-names></string-name>, <string-name><surname>Sanacora</surname><given-names>G</given-names></string-name></person-group> (<year>2021</year>) <article-title>Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial</article-title>. <source>Psychother Psychosom</source><volume>90</volume>:<fpage>318</fpage>–<lpage>327</lpage>.<pub-id pub-id-type="pmid">34186531</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0051">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wright</surname><given-names>DB</given-names></string-name>, <string-name><surname>Loftus</surname><given-names>EF</given-names></string-name></person-group> (<year>1999</year>) <article-title>Measuring dissociation: comparison of alternative forms of the dissociative experiences scale</article-title>. <source>Am J Psychol</source><volume>112</volume>:<fpage>497</fpage>–<lpage>519</lpage>.<pub-id pub-id-type="pmid">10696264</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0052">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zanos</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal> (<year>2016</year>) <article-title>NMDAR inhibition-independent antidepressant actions of ketamine metabolites</article-title>. <source>Nature</source><volume>533</volume>:<fpage>481</fpage>–<lpage>486</lpage>.<pub-id pub-id-type="pmid">27144355</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0053">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zanos</surname><given-names>P</given-names></string-name>, <string-name><surname>Gould</surname><given-names>TD</given-names></string-name></person-group> (<year>2018</year>) <article-title>Mechanisms of ketamine action as an antidepressant</article-title>. <source>Mol Psychiatry</source><volume>23</volume>:<fpage>801</fpage>–<lpage>811</lpage>.<pub-id pub-id-type="pmid">29532791</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0055">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr.</suffix></string-name>, <string-name><surname>Singh</surname><given-names>JB</given-names></string-name>, <string-name><surname>Carlson</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Brutsche</surname><given-names>NE</given-names></string-name>, <string-name><surname>Ameli</surname><given-names>R</given-names></string-name>, <string-name><surname>Luckenbaugh</surname><given-names>DA</given-names></string-name>, <string-name><surname>Charney</surname><given-names>DS</given-names></string-name>, <string-name><surname>Manji</surname><given-names>HK</given-names></string-name></person-group> (<year>2006</year>) <article-title>A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression</article-title>. <source>Arch Gen Psychiatry</source><volume>63</volume>:<fpage>856</fpage>–<lpage>864</lpage>. <ext-link xlink:href="http://archpsyc.ama-assn.org/cgi/content/abstract/63/8/856" ext-link-type="uri">http://archpsyc.ama-assn.org/cgi/content/abstract/63/8/856</ext-link> (Not in File)<pub-id pub-id-type="pmid">16894061</pub-id>
</mixed-citation>
              </ref>
              <ref id="CIT0054">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr.</suffix></string-name>, <string-name><surname>Brutsche</surname><given-names>N</given-names></string-name>, <string-name><surname>Laje</surname><given-names>G</given-names></string-name>, <string-name><surname>Luckenbaugh</surname><given-names>DA</given-names></string-name>, <string-name><surname>Venkata</surname><given-names>SL</given-names></string-name>, <string-name><surname>Ramamoorthy</surname><given-names>A</given-names></string-name>, <string-name><surname>Moaddel</surname><given-names>R</given-names></string-name>, <string-name><surname>Wainer</surname><given-names>IW</given-names></string-name></person-group> (<year>2012</year>) <article-title>Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression</article-title>. <source>Biol Psychiatry</source><volume>72</volume>:<fpage>331</fpage>–<lpage>338</lpage>.<pub-id pub-id-type="pmid">22516044</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
